• Episode 8: Extended interview on dual antiplatelet therapy in 2025

  • Jan 30 2025
  • Length: 15 mins
  • Podcast

Episode 8: Extended interview on dual antiplatelet therapy in 2025

  • Summary

  • Host: Emer Joyce

    Guest: Gilles Montalescot

    Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1798?resource=interview

    Disclaimer

    ESC TV Today is supported by Bristol Myers Squibb.

    This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

    Declarations of interests

    Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

    Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Show More Show Less

What listeners say about Episode 8: Extended interview on dual antiplatelet therapy in 2025

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.